Navigation Links
Mouse gene shows new mechanism behind cardiac infarction in man

A gene that, in different variants, increases or decreases the level of atherosclerosis has been identified in mice. The corresponding human gene has been shown to play a role in the development of myocardial infarction.

The results of the study is published this week on Nature Genetics Online.

Researchers at Karolinska Institutet, in collaboration with the Jackson Laboratory in the USA, AstraZeneca and a Japanese research group, have scrutinised an area on chromosome 1 that is of demonstrable importance to the development of arteriosclerosis. The TNFSF4 gene was identified as the one responsible, as mice with mutations in this gene displayed a lower degree of atherosclerosis, while mice with more active variants of the gene displayed the opposite.

Studies of two patient groups revealed that a certain variant of the human homologue of the gene was more common in people who had a history of cardiac infarction than those without.

“This is an example of how an unbiased genetic strategy based on a mice model can teach us more about common human diseases,?says researcher Jacob Lagercrantz of the Gustav V research institute, Karolinska Institutet.

The gene codes for a protein called OX40L, which is involved in the activation of immunological T cells. These cells, in turn, play an important role in the pathogenesis of atherosclerosis and of a number of chronic inflammatory diseases. The new finding will spur further research into the relationship between the protein and cardiac infarction. Hopefully it will offer a new therapeutic technique for the treatment of atherosclerosis and thus reduce the risk of cardiac infarction.


'"/>

Source:News-Medical


Page: 1

Related biology news :

1. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
2. Mouse brain tumors mimic those in human genetic disorder
3. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
4. Mouse with designer liver has enhanced glucose tolerance, insulin response
5. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
6. Mouse genome much more complex than expected
7. Mouse study: New muscle-building agent beats all previous ones
8. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
9. Mouse to man: The story of chromosomes
10. Mouse mimics chronic leukemia, will aid drug development
11. Mouse study reveals new clues about virulence of 1918 influenza virus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseq™ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology: